Cytokinetics, Inc. (CYTK)

[H2R]

New SoS Analysis: Bullish.Financial Standing.

For those who like in depth analysis:

Since it's a subscription based site, I won't copy/paste the entire article, but I'll do a snippet of particular importance in the world of Biotech:

CYTK raised approximately $100 million during the second quarter which was in addition to the $100 million raised in Q1 2017 from the royalty monetization deal on omecamtiv with Royalty Pharma. The $100 million raised in Q2 2017 included an $83 million public stock offering underwritten by Morgan Stanley, $12 million from the completion of an at-the-market offering and $11 million from the exercise of warrants originating in a 2012 financing. As a result, CYTK ended the second quarter with $332 million in cash, cash equivalents and investments which represents over 24 months of going-forward cash burn based on current financial guidance.